Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 02, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 22, 2022
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 07, 2021
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Journal: Hematology (Amsterdam, Netherlands)
Published: March 06, 2020
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 18, 2019
Risk scoring for time to end-stage knee osteoarthritis: data from the Osteoarthritis Initiative.
Journal: Osteoarthritis and cartilage
Published: March 24, 2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Journal: British journal of haematology
Published: February 12, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Journal: The Lancet. Haematology
Published: January 30, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Journal: American journal of hematology
Published: October 19, 2018
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Journal: Leukemia & lymphoma
Published: October 03, 2018
Last Updated: 09/26/2026